(Q39085988)

English

Plasmodium falciparum anti-MSP1-19 antibodies induced by MSP1-42 and MSP1-19 based vaccines differed in specificity and parasite growth inhibition in terms of recognition of conserved versus variant epitopes

scientific article published on 18 September 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Plasmodium falciparum anti-MSP1-19 antibodies induced by MSP1-42 and MSP1-19 based vaccines differed in specificity and parasite growth inhibition in terms of recognition of conserved versus variant epitopes (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Plasmodium falciparum

0 references

1 reference

based on heuristic

inferred from title

parasite growth

1 reference

based on heuristic

inferred from title

author name string

George Hui

1

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Caryn Hashimoto

2

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

language of work or name

0 references

publication date

18 September 2006

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

948-956

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

The 3' portion of the gene for a Plasmodium yoelii merozoite surface antigen encodes the epitope recognized by a protective monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

A new rodent model to assess blood stage immunity to the Plasmodium falciparum antigen merozoite surface protein 119 reveals a protective role for invasion inhibitory antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1(19), predicts protection from malaria infection and high-density parasitemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Definition of T cell epitopes within the 19 kDa carboxylterminal fragment of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) and their role in immunity to malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Immunoglobulin G3 antibodies specific for the 19-kilodalton carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein 1 transfer protection to mice deficient in Fc-gammaRI receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Single-chain antibodies produced by phage display against the C-terminal 19 kDa region of merozoite surface protein-1 of Plasmodium yoelii reduce parasite growth following challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Nature and specificity of the required protective immune response that develops postchallenge in mice vaccinated with the 19-kilodalton fragment of Plasmodium yoelii merozoite surface protein 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Protective immune responses to the 42-kilodalton (kDa) region of Plasmodium yoelii merozoite surface protein 1 are induced by the C-terminal 19-kDa region but not by the adjacent 33-kDa region

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognise the first growth factor-like domain of merozoite surface protein-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Inhibitory and neutral antibodies to Plasmodium falciparum MSP119 form ring structures with their antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

The combined epidermal growth factor-like modules of Plasmodium yoelii Merozoite Surface Protein-1 are required for a protective immune response to the parasite

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Malaria parasite-inhibitory antibody epitopes on Plasmodium falciparum merozoite surface protein-1(19) mapped by TROSY NMR.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Allelic dimorphism in a surface antigen gene of the malaria parasite Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Plasmodium falciparum: allelic variation in the merozoite surface protein 1 gene in wild isolates from southern Vietnam

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Sequence heterogeneity of the C-terminal, Cys-rich region of the merozoite surface protein-1 (MSP-1) in field samples of Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Plasmodium falciparum: variations in the C-terminal cysteine-rich region of the merozoite surface protein-1 in field samples among Indian isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Plasmodium falciparum: variations within the C-terminal region of merozoite surface antigen-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Mapping of the region predominantly recognized by antibodies to the Plasmodium falciparum merozoite surface antigen MSA 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

In vivo expression and immunological studies of the 42-kilodalton carboxyl-terminal processing fragment of Plasmodium falciparum merozoite surface protein 1 in the baculovirus-silkworm system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Expression and antigenicity of Plasmodium falciparum major merozoite surface protein (MSP1(19)) variants secreted from Saccharomyces cerevisiae.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Expression of an immunologically reactive merozoite surface protein (MSP-1(42)) in E. coli

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Disulfide bonds in merozoite surface protein 1 of the malaria parasite impede efficient antigen processing and affect the in vivo antibody response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Solution structure of an EGF module pair from the Plasmodium falciparum merozoite surface protein 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Crystal structure of a Fab complex formed with PfMSP1-19, the C-terminal fragment of merozoite surface protein 1 from Plasmodium falciparum: a malaria vaccine candidate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese vi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Precise epitope mapping of malaria parasite inhibitory antibodies by TROSY NMR cross-saturation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kiloDalton fragments expressed in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

Predicted and observed alleles of Plasmodium falciparum merozoite surface protein-1 (MSP-1), a potential malaria vaccine antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunological cross-reactivity of the C-terminal 42-kilodalton fragment of Plasmodium falciparum merozoite surface protein 1 expressed in baculovirus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.041

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2006.08.041

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39085988&oldid=1976950474"